BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2961 related articles for article (PubMed ID: 32727811)

  • 1. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
    Wei J; Zhao J; Han M; Meng F; Zhou J
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.
    Madduri D; Parekh S; Campbell TB; Neumann F; Petrocca F; Jagannath S
    J Med Case Rep; 2021 Feb; 15(1):90. PubMed ID: 33608053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome-An Observational Pilot Study.
    Notz Q; Schmalzing M; Wedekink F; Schlesinger T; Gernert M; Herrmann J; Sorger L; Weismann D; Schmid B; Sitter M; Schlegel N; Kranke P; Wischhusen J; Meybohm P; Lotz C
    Front Immunol; 2020; 11():581338. PubMed ID: 33123167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals.
    Ni L; Ye F; Cheng ML; Feng Y; Deng YQ; Zhao H; Wei P; Ge J; Gou M; Li X; Sun L; Cao T; Wang P; Zhou C; Zhang R; Liang P; Guo H; Wang X; Qin CF; Chen F; Dong C
    Immunity; 2020 Jun; 52(6):971-977.e3. PubMed ID: 32413330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expansion of SARS-CoV-2-Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients.
    Varnaitė R; García M; Glans H; Maleki KT; Sandberg JT; Tynell J; Christ W; Lagerqvist N; Asgeirsson H; Ljunggren HG; Ahlén G; Frelin L; Sällberg M; Blom K; Klingström J; Gredmark-Russ S
    J Immunol; 2020 Nov; 205(9):2437-2446. PubMed ID: 32878912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The laboratory tests and host immunity of COVID-19 patients with different severity of illness.
    Wang F; Hou H; Luo Y; Tang G; Wu S; Huang M; Liu W; Zhu Y; Lin Q; Mao L; Fang M; Zhang H; Sun Z
    JCI Insight; 2020 May; 5(10):. PubMed ID: 32324595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longer Duration of SARS-CoV-2 Infection in a Case of Mild COVID-19 With Weak Production of the Specific IgM and IgG Antibodies.
    Guo X; Zeng L; Huang Z; He Y; Zhang Z; Zhong Z
    Front Immunol; 2020; 11():1936. PubMed ID: 32849650
    [No Abstract]   [Full Text] [Related]  

  • 8. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques.
    Deng W; Bao L; Liu J; Xiao C; Liu J; Xue J; Lv Q; Qi F; Gao H; Yu P; Xu Y; Qu Y; Li F; Xiang Z; Yu H; Gong S; Liu M; Wang G; Wang S; Song Z; Liu Y; Zhao W; Han Y; Zhao L; Liu X; Wei Q; Qin C
    Science; 2020 Aug; 369(6505):818-823. PubMed ID: 32616673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection.
    Lin Q; Zhu L; Ni Z; Meng H; You L
    J Microbiol Immunol Infect; 2020 Oct; 53(5):821-822. PubMed ID: 32249185
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term infection of SARS-CoV-2 changed the body's immune status.
    Lin L; Luo S; Qin R; Yang M; Wang X; Yang Q; Zhang Y; Wang Q; Zhu R; Fan H; Wang H; Hu Y; Wang L; Hu D
    Clin Immunol; 2020 Sep; 218():108524. PubMed ID: 32659373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expansion of plasmablasts and loss of memory B cells in peripheral blood from COVID-19 patients with pneumonia.
    De Biasi S; Lo Tartaro D; Meschiari M; Gibellini L; Bellinazzi C; Borella R; Fidanza L; Mattioli M; Paolini A; Gozzi L; Jaacoub D; Faltoni M; Volpi S; Milić J; Sita M; Sarti M; Pucillo C; Girardis M; Guaraldi G; Mussini C; Cossarizza A
    Eur J Immunol; 2020 Sep; 50(9):1283-1294. PubMed ID: 32910469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 infection protects against rechallenge in rhesus macaques.
    Chandrashekar A; Liu J; Martinot AJ; McMahan K; Mercado NB; Peter L; Tostanoski LH; Yu J; Maliga Z; Nekorchuk M; Busman-Sahay K; Terry M; Wrijil LM; Ducat S; Martinez DR; Atyeo C; Fischinger S; Burke JS; Slein MD; Pessaint L; Van Ry A; Greenhouse J; Taylor T; Blade K; Cook A; Finneyfrock B; Brown R; Teow E; Velasco J; Zahn R; Wegmann F; Abbink P; Bondzie EA; Dagotto G; Gebre MS; He X; Jacob-Dolan C; Kordana N; Li Z; Lifton MA; Mahrokhian SH; Maxfield LF; Nityanandam R; Nkolola JP; Schmidt AG; Miller AD; Baric RS; Alter G; Sorger PK; Estes JD; Andersen H; Lewis MG; Barouch DH
    Science; 2020 Aug; 369(6505):812-817. PubMed ID: 32434946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics of four cancer patients with SARS-CoV-2 infection in Wuhan, China.
    Song SH; Chen TL; Deng LP; Zhang YX; Mo PZ; Gao SC; Hu WJ; Xiong Y; Ma ZY
    Infect Dis Poverty; 2020 Jul; 9(1):82. PubMed ID: 32616030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of Early SARS-CoV-2 and Cross-Coronavirus Immunity.
    Loos C; Atyeo C; Fischinger S; Burke J; Slein MD; Streeck H; Lauffenburger D; Ryan ET; Charles RC; Alter G
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32878931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of severe acute respiratory syndrome coronavirus 2 RNA test results in a patient with fatal coronavirus disease 2019: a case report.
    Shao C; Liu H; Meng L; Sun L; Wang Y; Yue Z; Kong H; Li H; Weng H; Lv F; Jin R
    Hum Pathol; 2020 Jul; 101():82-88. PubMed ID: 32437706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.
    Conti P; Caraffa A; Tetè G; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G
    J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1629-1632. PubMed ID: 32945158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine Storm Drugs Move from CAR T to COVID-19.
    Cancer Discov; 2020 Jul; 10(7):OF8. PubMed ID: 32371479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing Administration of CAR T-Cell Therapy During the COVID-19 Pandemic.
    Bishop MR
    Clin Adv Hematol Oncol; 2020 Jul; 18(7):400-403. PubMed ID: 32903251
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients.
    Mushtaq MU; Shahzad M; Chaudhary SG; Luder M; Ahmed N; Abdelhakim H; Bansal R; Balusu R; DeJarnette S; Divine C; Kribs R; Shune L; Singh AK; Ganguly S; Abhyankar SH; McGuirk JP
    Transplant Cell Ther; 2021 Sep; 27(9):796.e1-796.e7. PubMed ID: 34256172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Severe acute respiratory syndrome coronavirus 2 infection in renal transplant recipients: A case report].
    Li QY; Cheng Q; Zhao ZL; Dai NN; Zeng L; Zhu L; Guo W; Li C; Wang JH; Li S; Ge QG; Shen N
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Aug; 52(4):780-784. PubMed ID: 32773818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 149.